Company profile

Onchilles Pharma Inc

Privately held: no public share price (Private oncology biotech; $7M Series A (2021) and $25M Series A1 (Nov 2025), no IPO. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.businesswire.com/news/home/20251107100720/en/Onchilles-Pharma-Publishes-Landmark-ELANE-Pathway-Study-and-Advances-N17350-Toward-the-Clinic-With-New-Financing-and-Leading-Clinical-Advisor]) · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
N17350
Phase 2
Neutrophil elastase (ELANE) pathway - N17350 acts as a directBiologic — subtype unspecified
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.